ArticleAntimicrobial agents and chemotherapy2015
Neutralization of staphylococcal enterotoxin B by an aptamer antagonist.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Recent Advances in Aptamer-Based Biosensors for Bacterial Detection.Biosensors · 2024Review
- Bacteriological diagnosis of osteoarticular infections caused byFrontiers in pediatrics · 2024Review
- The SEB1741 Aptamer Is an Efficient Tool for Blocking CD4+ T Cell Activation Induced by Staphylococcal Enterotoxin B.Molecules (Basel, Switzerland) · 2023Article
- A colorimetric aptasensor based on gold nanoparticles for detection of microbial toxins: an alternative approach to conventional methods.Analytical and bioanalytical chemistry · 2022Review
- Potential applications of aptamers in veterinary science.Veterinary research · 2021Review
- Aptamers: An Emerging Tool for Diagnosis and Therapeutics in Tuberculosis.Frontiers in cellular and infection microbiology · 2021Review
- Review
- Novel Detection of Nasty Bugs, Prevention Is Better than Cure.International journal of molecular sciences · 2020Review
- Recent Progress in the Identification of Aptamers Against Bacterial Origins and Their Diagnostic Applications.International journal of molecular sciences · 2020Review
- Therapeutic applications of nucleic acid aptamers in microbial infections.Journal of biomedical science · 2020Review
- Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing.Sensors (Basel, Switzerland) · 2015Review
- Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics.Molecules (Basel, Switzerland) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcal enterotoxin B (SEB) is a major virulence factor for staphylococcal toxic shock syndrome (TSS). SEB activates a large subset of the T lymphocytic population, releasing proinflammatory cytokines. Blocking SEB-initiated toxicity may be an effective strategy for treating TSS. Using a process known as systematic evolution of ligands by exponential enrichment (SELEX), we identified an aptamer that can antagonize SEB with nanomolar binding affinity (Kd = 64 nM). The aptamer antagonist effectively inhibits SEB-mediated proliferation and cytokine secretion in human peripheral blood mononuclear cells. Moreover, a PEGylated aptamer antagonist significantly reduced mortality in a "double-hit" mouse model of SEB-induced TSS, established via sensitization with d-galactosamine followed by SEB challenge. Therefore, our novel aptamer antagonist may offer potential therapeutic efficacy against SEB-mediated TSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.